β-defensin 35 Inhibitors
β-defensin 35 inhibitors represent a class of compounds that specifically target the β-defensin 35 (DEFB135) protein, a member of the defensin family known for its antimicrobial peptide properties. Defensins are small, cysteine-rich peptides characterized by their ability to bind to and permeabilize cellular membranes. They typically contain six conserved cysteine residues that form three disulfide bonds, contributing to their structural stability. β-defensin 35, like other β-defensins, exhibits a characteristic three-stranded β-sheet structure stabilized by these disulfide linkages. Inhibitors of β-defensin 35 function by interfering with the protein's ability to engage in interactions at the molecular level, often by blocking binding sites or altering conformational flexibility. This inhibition can occur via direct interaction with the defensin molecule or through indirect modulation of the surrounding biochemical environment that supports its activity.
The mechanism by which β-defensin 35 inhibitors achieve their function can vary based on the inhibitor's structural properties. For instance, some inhibitors might function by disrupting the dimerization or oligomerization of β-defensin 35, processes that are essential for its ability to interact with cellular targets. Others may act by blocking the recognition and binding of β-defensin 35 to its substrates or receptors, often through competitive or allosteric inhibition. Such interactions can alter the electrostatic charge distribution or hydrophobicity of β-defensin 35, impacting its ability to embed into lipid bilayers or interact with other macromolecules. Furthermore, these inhibitors can be designed to exploit the specific conformational dynamics of β-defensin 35, selectively stabilizing inactive forms of the protein. As a result, β-defensin 35 inhibitors can be highly specific to their target, allowing for precise modulation of its activity in various biochemical pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
PARP inhibitor disrupting DNA repair. Niraparib indirectly inhibits β-defensin 35 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 35 transcription under conditions of cellular stress. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. Wortmannin indirectly hampers β-defensin 35, as PI3K/AKT signaling is implicated in the regulation of β-defensin 35 transcription by modulating specific transcription factors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor targeting JAK-STAT signaling. Ruxolitinib indirectly suppresses β-defensin 35, as the JAK-STAT pathway regulates the transcription of β-defensin 35 by activating STAT proteins. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 35 by blocking NFAT activation, a key regulator of β-defensin 35 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 35 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 35 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 35, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 35. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 35 by altering histone acetylation, influencing the accessibility of the β-defensin 35 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 35, as HIF-1α enhances β-defensin 35 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $169.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 35, as TLR4 activation is known to upregulate β-defensin 35 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 35 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 35 through control of translation initiation. | ||||||